What if... the right business approach could speed up development of cancer treatments?

The Prostate Centre's Translational Research Initiative for Accelerated Discovery and Development (CECR)

 

A Canadian technology that could outsmart cancer has scored a major investment from Roche, a pharmaceutical giant with more than 600 employees in Canada and over 90,000 globally. The licensing deal worth up to US$140 million is the largest ever made by the University of British Columbia, and much of the credit goes to PC-TRiADD – the commercialization arm of the Vancouver Prostate Centre. PC-TRiADD applied its business acumen to the scientific process to identify the most promising technologies, protect the intellectual property (IP) and generate the scientific data required to support IP claims and generate regulatory submissions to Health Canada.The new drug candidate outsmarts cancer by attacking the same male hormone (androgen) receptor that promotes tumour growth. The goal is to have a simple pill that prostate cancer patients can take daily.

PC-TRiADD’s general support provided an environment with the right tools and people to cultivate innovation, and PC-TRiADD’s specific support of the AR-DBD inhibitor project significantly de-risked the technology. This was not a typical academic project available for licensing – the licensed patents were backed by a body of work that brought the technology to the next level, which resulted in UBC’s largest license.Brad Wheeler, Technology Transfer Manager, University of British Columbia